+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
GalNAc Delivery Technology Market by Therapeutic Area (Cardiovascular Diseases, Liver Diseases, Metabolic Disorders), Clinical Stage (Commercial, Phase I/II, Phase III), Mechanism of Action, End User - Global Forecast 2025-2030- Product Image
GalNAc Delivery Technology Market by Therapeutic Area (Cardiovascular Diseases, Liver Diseases, Metabolic Disorders), Clinical Stage (Commercial, Phase I/II, Phase III), Mechanism of Action, End User - Global Forecast 2025-2030- Product Image
New

GalNAc Delivery Technology Market by Therapeutic Area (Cardiovascular Diseases, Liver Diseases, Metabolic Disorders), Clinical Stage (Commercial, Phase I/II, Phase III), Mechanism of Action, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6121685
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Since its inception, GalNAc delivery technology has redefined the paradigm of targeted nucleic acid therapeutics by enabling highly specific hepatocyte uptake through N-acetylgalactosamine ligands. This precision approach has addressed longstanding challenges in oligonucleotide delivery, such as off-target distribution and systemic toxicity, thereby unlocking the full potential of RNA-based drugs. As a result, stakeholders across the pharmaceutical and biotechnology landscape are recalibrating their research and development strategies to integrate GalNAc conjugation within diverse therapeutic programs.

This executive summary synthesizes critical developments shaping the GalNAc delivery ecosystem, encompassing technological advancements, regulatory dynamics, geopolitical influences, and evolving stakeholder priorities. It establishes a foundation for understanding how targeted delivery mechanisms are accelerating clinical successes, informing strategic investment decisions, and forging new partnerships. Subsequent sections delve into transformative shifts in the competitive environment, analyze the cumulative effects of United States tariff adjustments set for 2025, and present granular segmentation and regional insights. Finally, this document offers forward-looking recommendations, outlines the rigorous methodology underpinning our analysis, and concludes with a compelling call-to-action to leverage these insights for sustainable growth.

Mapping Key Disruptive Forces Reshaping the GalNAc Delivery Arena as RNA Therapeutics Gain Momentum Amidst Technological and Regulatory Shifts

The GalNAc delivery landscape has undergone transformative shifts, driven by breakthroughs in ligand design, enhanced endosomal escape strategies, and integrated formulation platforms. Recent clinical validations, including multiple phase III successes, have underscored the compatibility of GalNAc conjugates with a range of oligonucleotide modalities, boosting confidence among investors and accelerating therapeutic pipelines across cardiovascular, metabolic, and rare disease segments. In parallel, regulatory agencies have issued updated guidance on oligonucleotide conjugates, streamlining approval pathways and fostering broader adoption.

Moreover, strategic alliances between biotech innovators and large pharmaceutical corporations have proliferated, facilitating access to advanced manufacturing capabilities and global distribution networks. As competition intensifies from alternative delivery approaches such as lipid nanoparticles and exosome-based systems, organizations are prioritizing differentiation through proprietary GalNAc architectures that enhance receptor binding affinity and intracellular release kinetics. Collectively, these factors are redefining market dynamics, with an emphasis on agility, cross-functional collaboration, and data-driven optimization to deliver next-generation nucleic acid therapies.

Analyzing the Cumulative Consequences of 2025 United States Tariff Revisions on GalNAc Delivery Supply Chains Cost Structures and Competitive Dynamics

Anticipated tariff adjustments in the United States during 2025 present a pivotal challenge for manufacturers and researchers relying on GalNAc delivery components sourced globally. Increased duties on specialized raw materials, including N-acetylgalactosamine derivatives and custom oligonucleotide building blocks, are projected to elevate production costs and squeeze profit margins. These fiscal pressures necessitate a strategic reevaluation of supplier portfolios, prompting many organizations to diversify procurement channels and negotiate long-term agreements to lock in favorable pricing.

In response, several stakeholders are exploring vertical integration of key synthesis capabilities and investing in domestic manufacturing infrastructure to mitigate exposure to import duties. Concurrently, supply chain resilience has become paramount, with risk assessments driving inventory buffers and dual-sourcing strategies. Although initial capital outlays may rise, these measures are expected to yield more predictable lead times and insulation from future tariff volatility. Ultimately, the 2025 tariff landscape will catalyze a shift toward more robust supply chain architectures and heightened collaboration between procurement, R&D, and finance functions.

Unveiling Segmentation Insights That Illuminate Therapeutic Focus Clinical Stages Mechanisms of Action and End User Dynamics in GalNAc Delivery

A nuanced understanding of therapeutic area segmentation reveals that cardiovascular diseases represent a dominant focus for GalNAc delivery applications, notably targeting atherosclerosis with siRNA therapeutics and dyslipidemia through antisense modalities. In parallel, the liver disease segment encompasses both chronic hepatitis B programs and advanced candidates for nonalcoholic steatohepatitis, each leveraging the inherent hepatocyte affinity of GalNAc platforms. Metabolic disorder initiatives, such as those addressing familial hypercholesterolemia and primary hyperoxaluria, are harnessing precision oligonucleotides to modulate gene expression, while oncology efforts concentrate on hepatocellular carcinoma therapies that exploit GalNAc’s selective uptake for potent anticancer payloads. This breadth of therapeutic focus underscores the versatility of GalNAc conjugation across diverse disease states.

Clinical stage segmentation further highlights a balanced distribution of programs, spanning in-market commercial products, late-stage phase III trials, and exploratory preclinical research. Early clinical endeavors in phase I and phase II continue to expand, reflecting strong investor appetite and a robust pipeline of novel candidates. Mechanistic diversity within the platform is equally pronounced, encompassing antisense oligonucleotides differentiated by morpholino or phosphorothioate backbones, advanced gene editing constructs employing CRISPR-Cas9 and TALEN systems, mRNA therapies classified as either therapeutic mRNA or vaccine mRNA, and RNA interference approaches ranging from shRNA to siRNA. These mechanistic variations enable tailored therapeutic profiles that address specific disease characteristics. End user segmentation spans academic institutions driving foundational research, biotechnology firms spearheading innovation, contract research organizations accelerating preclinical and clinical execution, and pharmaceutical companies executing late-stage development and commercialization. Collectively, these segmentation insights illuminate the multidimensional nature of the GalNAc delivery ecosystem and inform strategic positioning across the value chain.

Deciphering Regional Dynamics in Americas Europe Middle East Africa and Asia Pacific That Drive the Adoption and Innovation of GalNAc Delivery Technologies

Regional analysis reveals distinct drivers influencing GalNAc delivery adoption across major geographies. In the Americas, particularly the United States, a robust venture capital environment and leading research institutions have catalyzed rapid clinical advancement and commercialization of GalNAc conjugates. Public-private collaborations and streamlined regulatory pathways have bolstered capacity for large phase III programs, while strategic manufacturing investments have enhanced local production capabilities and minimized supply chain disruptions.

In Europe, Middle East, and Africa, regulators are aligning frameworks with global standards, facilitating multinational trials and cross-border licensing agreements. Pharmaceutical alliances in this region are emphasizing cost-effective production and market access strategies, responding to diverse healthcare reimbursement models. Meanwhile, Asia-Pacific markets exhibit a rising focus on domestic innovation hubs, with government incentives fueling biotech incubators and public research initiatives. Collaborative networks spanning China, Japan, and South Korea are driving discovery efforts and exploring novel GalNAc formulations, positioning the region as a complementary contributor to the global value chain.

Examining Leading Biotech and Pharmaceutical Contributors Advancing GalNAc Delivery Innovations Through Strategic Collaborations Investments and Pipeline Developments

Several pioneering organizations are shaping the trajectory of GalNAc delivery technology through strategic investments and collaborative endeavors. Leading biotechnology firms have established proprietary ligand conjugation platforms, securing intellectual property portfolios that confer competitive differentiation. These entities are actively exploring co-development agreements with large pharmaceutical corporations to leverage established commercialization channels and broaden therapeutic reach.

Major pharmaceutical players are also investing in in-house capabilities, acquiring or licensing specialized synthesis facilities to produce high-purity oligonucleotide intermediates at scale. Partnerships between contract research organizations and academic laboratories have expedited process optimization and formulation refinement, while technology providers specializing in delivery vectors are integrating advanced analytics to monitor pharmacokinetics and biodistribution in real time. Collectively, these company-driven initiatives are accelerating the translation of GalNAc conjugates from bench to bedside.

Empowering Industry Leaders With Actionable Strategies to Navigate Complexity Maximize Adoption and Fuel Growth in the GalNAc Delivery Therapeutics Landscape

Industry leaders should prioritize investments in enhanced endosomal escape mechanisms to elevate intracellular release rates and maximize therapeutic efficacy. By integrating novel peptide-based or pH-responsive carriers into existing GalNAc conjugates, organizations can differentiate their pipelines and address residual delivery challenges. Additionally, aligning procurement strategies with predictive analytics will enable proactive supplier risk management and cost containment in the face of evolving tariff landscapes.

Collaborative frameworks between R&D, regulatory affairs, and commercial teams are essential to expedite clinical development and market entry. Early engagement with global regulatory bodies can clarify safety requirements for conjugated oligonucleotides and preempt potential approval hurdles. Moreover, strengthening academic partnerships will ensure access to cutting-edge discovery platforms and foster talent pipelines adept at navigating complex biologics manufacturing. Finally, embracing digital transformation across manufacturing and data analytics workflows will enhance process reproducibility and deliver actionable insights to support continuous optimization.

Detailing the Rigorous Multidimensional Research Methodology Combining Qualitative Interviews Quantitative Data Analysis and Expert Validation for Robust Insights

This analysis is founded upon a rigorous, multi-tiered research methodology that integrates qualitative expertise with quantitative rigor. Primary insights were gathered through in-depth interviews with senior executives from pharmaceutical and biotechnology organizations, research directors at academic centers, and regulatory consultants with specialized expertise in oligonucleotide conjugates. These interviews provided nuanced perspectives on technological hurdles, strategic priorities, and emerging opportunities within the GalNAc delivery domain.

Secondary research encompassed a comprehensive review of peer-reviewed scientific literature, patent filings, clinical trial registries, and regulatory guidance documents to establish a factual baseline. Quantitative data was sourced from proprietary databases tracking development pipelines, grant funding patterns, and publication metrics. Analytical frameworks such as SWOT analysis, PESTLE evaluation, and competitive benchmarking were applied to synthesize findings and identify priority areas. All insights were subject to multi-layered validation by an expert advisory panel, ensuring accuracy, relevance, and robustness of conclusions.

Synthesizing Core Findings to Illuminate the Transformative Potential of GalNAc Delivery Technology and Outline Its Path Forward in Precision Medicine

The convergence of advanced ligand engineering, evolving regulatory ecosystems, and adaptive supply chain strategies has positioned GalNAc delivery technology as a transformative force in precision therapeutics. Segmentation analysis underscores the platform’s versatility across cardiovascular, hepatic, metabolic, and oncological indications, while regional insights reveal diverse adoption patterns driven by funding landscapes and policy frameworks. Company-driven innovation and collaborative partnerships have accelerated clinical progress, and actionable recommendations chart a path for leaders to optimize delivery performance and mitigate operational risks.

Collectively, these findings illuminate the sustained momentum behind GalNAc conjugates and highlight the critical success factors for stakeholders aiming to capitalize on this high-growth domain. Continued investment in next-generation formulations, strategic alignment with regulatory priorities, and proactive supply chain resilience will be essential to unlocking the full potential of targeted nucleic acid therapies.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapeutic Area
    • Cardiovascular Diseases
      • Atherosclerosis
      • Dyslipidemia
    • Liver Diseases
      • Hepatitis B
      • Non Alcoholic Steatohepatitis
    • Metabolic Disorders
      • Familial Hypercholesterolemia
      • Primary Hyperoxaluria
    • Oncology
      • Hepatocellular Carcinoma
  • Clinical Stage
    • Commercial
    • Phase I/II
      • Phase I
      • Phase II
    • Phase III
    • Preclinical
  • Mechanism Of Action
    • Antisense Oligonucleotides
      • Morpholino
      • Phosphorothioate
    • Gene Editing
      • Crispr Cas9
      • Talen
    • Mrna Therapies
      • Therapeutic Mrna
      • Vaccine Mrna
    • Rna Interference
      • ShRNA
      • SiRNA
  • End User
    • Academic Institutions
    • Biotechnology Firms
    • Contract Research Organizations
    • Pharmaceutical Companies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Alnylam Pharmaceuticals, Inc.
  • Novartis AG
  • Ionis Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Dicerna Pharmaceuticals, Inc.
  • Silence Therapeutics plc
  • Akcea Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Sirnaomics Co., Ltd.
  • Aligos Therapeutics, Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advancements in high-throughput screening of triantennary GalNAc conjugates to improve liver-specific delivery efficiency
5.2. Emergence of multi-valent GalNAc conjugation platforms enabling simultaneous targeting of multiple hepatic receptors
5.3. Integration of novel chemical modifications in GalNAc backbones to enhance endosomal escape and therapeutic potency
5.4. Expansion of GalNAc delivery applications beyond RNAi into antisense oligonucleotides and mRNA therapeutics pipelines
5.5. Strategic collaborations between biotech and CMOs to scale up GalNAc conjugate manufacturing capacity for commercial demand
5.6. Regulatory breakthroughs allowing accelerated approval pathways for GalNAc-based therapies in rare metabolic disorders
5.7. Cost optimization strategies through process intensification and reagent recycling in GalNAc conjugation manufacturing workflows
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. GalNAc Delivery Technology Market, by Therapeutic Area
8.1. Introduction
8.2. Cardiovascular Diseases
8.2.1. Atherosclerosis
8.2.2. Dyslipidemia
8.3. Liver Diseases
8.3.1. Hepatitis B
8.3.2. Non Alcoholic Steatohepatitis
8.4. Metabolic Disorders
8.4.1. Familial Hypercholesterolemia
8.4.2. Primary Hyperoxaluria
8.5. Oncology
8.5.1. Hepatocellular Carcinoma
9. GalNAc Delivery Technology Market, by Clinical Stage
9.1. Introduction
9.2. Commercial
9.3. Phase I/II
9.3.1. Phase I
9.3.2. Phase II
9.4. Phase III
9.5. Preclinical
10. GalNAc Delivery Technology Market, by Mechanism of Action
10.1. Introduction
10.2. Antisense Oligonucleotides
10.2.1. Morpholino
10.2.2. Phosphorothioate
10.3. Gene Editing
10.3.1. Crispr Cas9
10.3.2. Talen
10.4. Mrna Therapies
10.4.1. Therapeutic Mrna
10.4.2. Vaccine Mrna
10.5. Rna Interference
10.5.1. ShRNA
10.5.2. SiRNA
11. GalNAc Delivery Technology Market, by End User
11.1. Introduction
11.2. Academic Institutions
11.3. Biotechnology Firms
11.4. Contract Research Organizations
11.5. Pharmaceutical Companies
12. Americas GalNAc Delivery Technology Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa GalNAc Delivery Technology Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific GalNAc Delivery Technology Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Alnylam Pharmaceuticals, Inc.
15.3.2. Novartis AG
15.3.3. Ionis Pharmaceuticals, Inc.
15.3.4. Arrowhead Pharmaceuticals, Inc.
15.3.5. Dicerna Pharmaceuticals, Inc.
15.3.6. Silence Therapeutics plc
15.3.7. Akcea Therapeutics, Inc.
15.3.8. F. Hoffmann-La Roche Ltd.
15.3.9. Sirnaomics Co., Ltd.
15.3.10. Aligos Therapeutics, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. GALNAC DELIVERY TECHNOLOGY MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GALNAC DELIVERY TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. GALNAC DELIVERY TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. GALNAC DELIVERY TECHNOLOGY MARKET: RESEARCHAI
FIGURE 24. GALNAC DELIVERY TECHNOLOGY MARKET: RESEARCHSTATISTICS
FIGURE 25. GALNAC DELIVERY TECHNOLOGY MARKET: RESEARCHCONTACTS
FIGURE 26. GALNAC DELIVERY TECHNOLOGY MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GALNAC DELIVERY TECHNOLOGY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY DYSLIPIDEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY DYSLIPIDEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY NON ALCOHOLIC STEATOHEPATITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY NON ALCOHOLIC STEATOHEPATITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY FAMILIAL HYPERCHOLESTEROLEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY FAMILIAL HYPERCHOLESTEROLEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PRIMARY HYPEROXALURIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PRIMARY HYPEROXALURIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COMMERCIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE II, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE III, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PRECLINICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MORPHOLINO, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MORPHOLINO, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHOSPHOROTHIOATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHOSPHOROTHIOATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CRISPR CAS9, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CRISPR CAS9, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY TALEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY TALEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC MRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC MRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY VACCINE MRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY VACCINE MRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY SHRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY SHRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY SIRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY SIRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 157. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 158. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 159. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 160. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 161. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2024 (USD MILLION)
TABLE 162. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2025-2030 (USD MILLION)
TABLE 163. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 164. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 165. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 166. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 167. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
TABLE 168. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2025-2030 (USD MILLION)
TABLE 169. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2024 (USD MILLION)
TABLE 170. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2025-2030 (USD MILLION)
TABLE 171. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 172. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 173. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2024 (USD MILLION)
TABLE 174. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2025-2030 (USD MILLION)
TABLE 175. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
TABLE 176. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
TABLE 177. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2024 (USD MILLION)
TABLE 178. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2025-2030 (USD MILLION)
TABLE 179. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2024 (USD MILLION)
TABLE 180. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2025-2030 (USD MILLION)
TABLE 181. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. CANADA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 184. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 185. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 186. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 187. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2024 (USD MILLION)
TABLE 188. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2025-2030 (USD MILLION)
TABLE 189. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 190. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 191. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 192. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 193. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
TABLE 194. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2025-2030 (USD MILLION)
TABLE 195. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2024 (USD MILLION)
TABLE 196. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2025-2030 (USD MILLION)
TABLE 197. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 198. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 199. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2024 (USD MILLION)
TABLE 200. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2025-2030 (USD MILLION)
TABLE 201. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
TABLE 202. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
TABLE 203. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2024 (USD MILLION)
TABLE 204. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2025-2030 (USD MILLION)
TABLE 205. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2024 (USD MILLION)
TABLE 206. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2025-2030 (USD MILLION)
TABLE 207. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. MEXICO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 290. UNITED KINGDOM GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 305. UNITED KINGDOM GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2024 (USD MILLION)
TABLE 306. UNITED KINGDOM GALNAC DELIVERY TECHNOLOGY MARKET SI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this GalNAc Delivery Technology market report include:
  • Alnylam Pharmaceuticals, Inc.
  • Novartis AG
  • Ionis Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Dicerna Pharmaceuticals, Inc.
  • Silence Therapeutics plc
  • Akcea Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Sirnaomics Co., Ltd.
  • Aligos Therapeutics, Inc.

Related Reports

GalNAc-Oligonucleotide Conjugates Market by Product Type (Antisense Oligonucleotides, Aptamers, MiRNA), Therapeutic Application (Infectious Diseases, Metabolic Disorders, Oncology), Route of Administration, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

GalNAc-Oligonucleotide Conjugates Market by Product Type (Antisense Oligonucleotides, Aptamers, MiRNA), Therapeutic Application (Infectious Diseases, Metabolic Disorders, Oncology), Route of Administration, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
GalNAc-based Drug Market by Indication (Genetic Disorders, Metabolic Syndrome, Oncology), Product Type (Antisense Oligonucleotide, Small Interfering Rna), Route of Administration, Clinical Trial Phase, End User - Global Forecast 2025-2030 - Product Image

GalNAc-based Drug Market by Indication (Genetic Disorders, Metabolic Syndrome, Oncology), Product Type (Antisense Oligonucleotide, Small Interfering Rna), Route of Administration, Clinical Trial Phase, End User - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
GalNac Conjugates Market by Therapeutic Area (Hepatic Disorders, Metabolic Disorders, Oncology), Indication (Hemophilia, Hypercholesterolemia, Liver Cancer), Molecule Type, Administration Route, End User - Global Forecast 2025-2030 - Product Image

GalNac Conjugates Market by Therapeutic Area (Hepatic Disorders, Metabolic Disorders, Oncology), Indication (Hemophilia, Hypercholesterolemia, Liver Cancer), Molecule Type, Administration Route, End User - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
GalNAc-siRNA Conjugates Market by Product Type (Biantennary, Monoantennary, Triantennary), Indication (Acute Hepatic Porphyria, Homozygous Familial Hypercholesterolemia, Primary Hyperoxaluria Type 1), End User, Distribution Channel, Formulation - Global Forecast 2025-2030 - Product Image

GalNAc-siRNA Conjugates Market by Product Type (Biantennary, Monoantennary, Triantennary), Indication (Acute Hepatic Porphyria, Homozygous Familial Hypercholesterolemia, Primary Hyperoxaluria Type 1), End User, Distribution Channel, Formulation - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
GalNAc & GalNAc Derivatives Market by Application (Diagnostics, Pharmaceuticals, Research), Product Type (GalNAc, GalNAc Conjugates), End User, Technology, Distribution Channel - Global Forecast 2025-2030 - Product Image

GalNAc & GalNAc Derivatives Market by Application (Diagnostics, Pharmaceuticals, Research), Product Type (GalNAc, GalNAc Conjugates), End User, Technology, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.